A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.
Pegbelfermin Shows Promise in Addressing Liver Fibrosis in MASH
MASLD Associated With 2-Fold Increase of Serious Bacterial Infection
GLP-1 RAs May Offer Broad Hepatic Benefits in MASH
New Therapies Expanding the MASH Treatment Landscape
Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH
New Hope and Persistent Challenges for MASH Treatment: Naim Alkhouri, MD
MASH Clinical Trials Historically Underrepresent Certain Groups
Lipid Metabolites Emerge as Noninvasive Diagnostic Tool in MASH
Mortality Declines but Incidence Rates Up for Cirrhosis and Other Chronic Liver Diseases
Promising Potential for FGF21 Analogs in MASH Management
MASH-Related PLC on the Rise in Young Adults
"Alarming Rise" of Global MASH-Related Primary Liver Cancer Incidence Since 2000
A Potential Early Biomarker for MASLD: Oxidized Apolipoproteins
Top 5 Most-Viewed Liver Cancer Content for 2024
Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation
Patients With HCC May Avoid Additional Treatment After Complete Response
Real-World Results of Durvalumab/Tremelimumab in U-HCC Show Promise Despite Line of Therapy
Study Highlights Increasing Global Health Burden of Liver Cancer
ICER to Assess Clinical Effectiveness, Value of 2 NASH Treatments